Publication Cover
Synthetic Communications
An International Journal for Rapid Communication of Synthetic Organic Chemistry
Volume 54, 2024 - Issue 4
150
Views
0
CrossRef citations to date
0
Altmetric
Correction

Correction

This article refers to:
Synthesis and characterization of four diastereomers of β-lactamase inhibitor drug intermediate

Article title: Synthesis and characterization of four diastereomers of β-lactamase inhibitor drug intermediate

Authors: Amit Pund, Aniruddha Varangaonkar, Vipul Rane, Vinod Ahirrao, Mohammad Rafeeq, Ravindra Yeole, and Arvind Merwade

Journal: LSYC: Synthetic Communications

DOI: https://doi.org/10.1080/00397911.2023.2290625

When this article was originally published online, abstract was not correctly included. The appropriate abstract is provided below.

Abstract:

A short and efficient stereo-specific synthesis of three stereoisomers (two diastereomer and one enantiomer) of Oxalate salt of benzyl (2S,5R)-5-(benzyloxyamino)piperidine-2-carboxylate (8) has been described. Compound 8 is a key intermediate in the synthesis of b-lactamase inhibitors, was synthesized in high diastereomeric excess using chirally pure L-pyroglutamic acid. In this report, we also describe a chiral high performance liquid chromatography (CHPLC) method to separate these isomers. The developed CHPLC method was validated for the accurate determination of the diastereomeric purity of compound 8.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.